

ASX Announcement

First-in-Human Clinical Trial Progress Update

SYDNEY Australia, 17 March 2020: Recce Pharmaceuticals Ltd (**ASX: RCE**) (**Company**), the Company developing a new class of broad-spectrum synthetic antibiotics, is pleased to provide an update on the progress to begin the first human trials of its lead antibiotic compound RECCE® 327.

Intravascular Phase I Human Clinical Trial

Recce advises it is in the final stages of executing a clinical trial agreement, for an independent Phase I intravascular safety assessment of RECCE® 327 antibiotic at an Australian-based trial facility. The Company remains on track to deliver this pivotal milestone within the current quarter, as previously stated.

Topical Phase I/II Human Clinical Trial Submission

Recce also advises it is working with a leading Australian teaching hospital to initiate an independent Phase I/II topical efficacy study involving patients with a range of bacterial wound, burn and skin infections. Updates and related details for this promising opportunity to help patients and clinicians seeking to address unmet medical needs will be disclosed as they progress.

Looking ahead

The Company's operational activities are progressing as normal and are well funded. Investors will be kept informed of any further updates in the time ahead.

This announcement has been approved for release by Executive Director James Graham.



ASX: RCE

Head Office: Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (02) 8075 4585 **F** +61 (02) 8075 4584

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a New Class of Synthetic Antibiotics with Broad Spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs.

Recce antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs.

Patented lead candidate RECCE® 327, wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms.

The FDA has awarded RECCE® 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

For more information, visit recce.com.au and connect with the Company on [Twitter](#), [LinkedIn](#) and [YouTube](#).

Executive Director

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 8075 4585
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com

recce.com.au
ACN 124 849 065

